Figure 3.
HDL NPs reduced GPx4 expression in leukemia cell lines leading to ferroptosis in HEL cells but not MV4-11 cells. (A) Western blot of GPx4 protein expression in MV4-11 (left) or HEL (right) leukemia cells treated with either PBS; HDL NPs at 10, 20, or 40 nM; or human native HDL for 48 and 72 hours. (B) C11 BODIBY oxidative lipid assay in HEL cells after treatment with HDL NPs at 20 or 50 nM. (C) Viability (MTS) assay of HEL cells treated at 2 to 100 nM HDL NPs without (red bars) or with the iron chelator Fer-1 (blue bars) and DFO (green bars). (D) C11 BODIBY oxidative lipid assay in MV4-11 cells after treatment with HDL NPs at 20 or 50 nM. (E) Viability (MTS) assay of MV4-11 cells treated at 2 to 100 nM HDL NPs without (red bars) or with iron chelator Fer-1 (blue bars) and DFO (green bars). Cntl, control; hHDL, human HDL.

HDL NPs reduced GPx4 expression in leukemia cell lines leading to ferroptosis in HEL cells but not MV4-11 cells. (A) Western blot of GPx4 protein expression in MV4-11 (left) or HEL (right) leukemia cells treated with either PBS; HDL NPs at 10, 20, or 40 nM; or human native HDL for 48 and 72 hours. (B) C11 BODIBY oxidative lipid assay in HEL cells after treatment with HDL NPs at 20 or 50 nM. (C) Viability (MTS) assay of HEL cells treated at 2 to 100 nM HDL NPs without (red bars) or with the iron chelator Fer-1 (blue bars) and DFO (green bars). (D) C11 BODIBY oxidative lipid assay in MV4-11 cells after treatment with HDL NPs at 20 or 50 nM. (E) Viability (MTS) assay of MV4-11 cells treated at 2 to 100 nM HDL NPs without (red bars) or with iron chelator Fer-1 (blue bars) and DFO (green bars). Cntl, control; hHDL, human HDL.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal